Vasculitis & polymyalgia rheumatica
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature
Authors' conclusion
This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate.
Study context
- Population
- Patients with relapsing giant cell arteritis (GCA) treated with JAK inhibitors (JAKi) at 13 centres in Spain and 1 in the US (01/2017–12/2022); 86% female, mean age 72.3plus 36 literature cases
- Participants
- 35 patients
- Exposure
- Baricitinib vs Tofacitinib vs Upadacitinib
- Baricitinibn = 15
- Tofacitinibn = 10
- Upadacitinibn = 10
- Outcome
- Clinical and complete remission (achieved and maintained), all JAKi
- Follow-up
- Median (IQR) 11 (6-15.5) months
Methodological detailsreal-world, systematic literature search, Prior therapy: 22 (63%) csDMARD (e.g., MTX), 30 (86%) biologics (e.g., tocilizumab)
- Real-world
- Systematic literature search
- Prior therapy: 22 (63%) csDMARD (e.g., MTX), 30 (86%) biologics (e.g., tocilizumab)
Main finding
As reported in the abstract
median (IQR) follow-up 11 (6-15.5) months
Clinical remission achieved and maintained
20
57%
Complete remission achieved and maintained
16
46%
Discontinued initial JAKi due to relapse
11
31%
Observational data: associations, not effects.
Further findings
Literature review of JAKi-treated GCA cases
- Additional JAKi-treated GCA cases identified, clinical improvement reported for the majority
- 36
Safety
Discontinuation of initial JAKi due to serious adverse events
- Discontinued due to serious adverse events
- 4 [11%]
- 15 (43%) discontinued the initial JAKi overall (relapse or serious adverse events)
Original publication
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. Published 5 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →